Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Jill Trinacty
Observed name:
Trinacty, Jill
Institutions:
Queensway-Carleton Hospital,
Bruyère
Observed institutions:
University of Ottawa,
Queensway-Carleton Hospital,
Ottawa Hospital,
LMC Diabetes & Endocrinology (Canada),
Bruyère
ORCID:
0009-0002-1774-9117
Observed ORCID:
0009-0002-1774-9117
OpenAlex ID:
A5019663013
Perioperative and periprocedural management of GLP-1 receptor-based agonists and SGLT2 inhibitors: narrative review and the STOP-GAP and STOP DKA-2 algorithms
2025
·
Ronald M. Goldenberg
, Jeremy D. Gilbert
, et al.
·
Current Medical Research and Opinion
·
23
Glucagon‐like peptide‐1 receptor agonists and the risk of nonarteritic anterior ischaemic optic neuropathy: A systematic review and meta‐analysis of observational studies
2025
·
Ronald M. Goldenberg
, Ronnie Aronson
, et al.
·
Diabetes Obesity and Metabolism
·
5
Perioperative and Periprocedural Management of Once-Weekly Insulin Treated Patients
2025
·
Robyn L. Houlden
, Jeremy D. Gilbert
, et al.
·
Endocrine Practice
·
5
Pharmacologic Glycemic Management of Type 2 Diabetes in Adults---2024 Update: An Opportunity Lost to Move Beyond First-line Metformin
2024
·
Jill Trinacty
, Ronald M. Goldenberg
·
Canadian Journal of Diabetes
·
1
Glucagon‐Like Peptide‐1 Medicines and Risk of Dysaesthesia: A Systematic Review, Meta‐Analysis and Meta‐Regression of Randomised Controlled Trials
2026
·
Ronald M. Goldenberg
, Christine Ibrahim
, et al.
·
Diabetes Obesity and Metabolism
Author response for "Glucagon-like peptide-1 medicines and risk of dysaesthesia: A systematic review, meta-analysis and meta-regression of randomised controlled trials"
2026
·
Ronald M. Goldenberg
, Christine Ibrahim
, et al.
·
Publons reviews and discussion
Author response for "Glucagon-like peptide-1 medicines and risk of dysaesthesia: A systematic review, meta-analysis and meta-regression of randomised controlled trials"
2026
·
Ronald M. Goldenberg
, Christine Ibrahim
, et al.
·
Publons reviews and discussion
Tirzepatide Versus Semaglutide and Cardiovascular Outcomes in Type 2 Diabetes With Established Cardiovascular Disease: An Indirect Treatment Comparison Meta‐Analysis
2026
·
Ronald M. Goldenberg
, Jill Trinacty
, et al.
·
Diabetes Obesity and Metabolism
Author response for "Tirzepatide versus semaglutide and cardiovascular outcomes in type 2 diabetes with established cardiovascular disease: an indirect treatment comparison meta-analysis"
2026
·
Ronald M. Goldenberg
, Jill Trinacty
, et al.
·
Publons reviews and discussion
Author response for "Glucagon-like peptide-1 receptor agonists and the risk of nonarteritic anterior ischaemic optic neuropathy: A systematic review and meta-analysis of observational studies"
2025
·
Goldenberg, Ronald M.
, Aronson, Ronnie
, et al.
·
Publons reviews and discussion
Glucagon-like-peptide 1 (GLP-1) Receptor Agonists in Rheumatologic Disease
2025
·
Jill Trinacty
, Krista Rostom
·
Canadian rheumatology today.
The impact of recent exposure to bictegravir, dolutegravir or elvitegravir on glycemic control in patients living with HIV and diabetes.
2022
·
Sehgal, Chandni
, Kanji, Salmaan
, et al.
·
TSpace (University of Toronto)
PDF
Time Spent in Glycemic Control After Initiating Treatment With Oral Semaglutide Versus Empagliflozin: An Exploratory Analysis of the PIONEER 2 Trial
2021
·
Jill Trinacty
, Julio Rosenstock
, et al.
·
Canadian Journal of Diabetes
End of Life: What Does That Mean for the Management of Adult Patients With Type 1 Diabetes?
2018
·
Jill Trinacty
, Erin Keely
·
Canadian Journal of Diabetes
Patient and Provider Experience with MyChart™ Access in Endocrinology and Metabolism Clinics
2017
·
Jill Trinacty
, Erin Keely
, et al.
·
Canadian Journal of Diabetes
Show more works
View as search
Works count:
16
Citation count:
34
H-index:
3
I10-index:
1
Year
Topic
Type